ADMA Biologics (NASDAQ: ADMA) net income
ADMA Biologics reported a net profit of $146.9m for fiscal 2025, 25.7% less than in fiscal 2024 ($197.7m). Its net margin was 28.8%. Earnings per share were $0.62.
ADMA Biologics's best year of the last 10 was fiscal 2024. The biggest drop was in fiscal 2025, −25.7%. It reported a loss in 8 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $146.9m | −25.7% | 28.8% | $0.62 |
| 2024 | $197.7m | — | 46.4% | $0.85 |
| 2023 | −$28.2m | — | −10.9% | −$0.13 |
| 2022 | −$65.9m | — | −42.8% | −$0.33 |
| 2021 | −$71.6m | — | −88.5% | −$0.51 |
| 2020 | −$75.7m | — | −179.4% | −$0.88 |
| 2019 | −$48.3m | — | −164.5% | — |
| 2018 | −$65.7m | — | −387.1% | — |
| 2017 | −$43.8m | — | −192.3% | — |
| 2016 | −$19.5m | — | −183.1% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
ADMA Biologics net income compared with its sector
By net income for its latest fiscal year, ADMA Biologics ranks 103rd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of ADMA Biologics, 28.8%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 101st | Harmony Biosciences | $158.7m | 18.3% |
| 102nd | Bausch Health Companies | $157.0m | 1.5% |
| 103rd | ADMA Biologics | $146.9m | 28.8% |
| 104th | Inspire Medical Systems | $145.4m | 15.9% |
| 105th | Ardent Health | $135.8m | 2.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of ADMA Biologics
- How much did ADMA Biologics earn in fiscal 2025?
- ADMA Biologics reported a net profit of $146.9m for fiscal 2025. In fiscal 2024 it reported a net profit of $197.7m.
- What are the earnings per share of ADMA Biologics?
- They were $0.62 in fiscal 2025, compared with $0.85 in fiscal 2024.
- What is the net margin of ADMA Biologics?
- In fiscal 2025 its net profit was 28.8% of its revenue.
- What was the most profitable year for ADMA Biologics?
- Of its last 10 fiscal years, fiscal 2024, with $197.7m.
- Where does ADMA Biologics rank in its sector by net income?
- It ranks 103rd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for ADMA Biologics come from?
- From the annual report (Form 10-K) that ADMA Biologics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that ADMA Biologics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on ADMA Biologics: the ADMA Biologics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.